Idogen aims to develop the company’s first two projects until clinical effect has been demonstrated and then enter into agreements on continued development and marketing together with major partners. As a strategic alternative, the company can develop the first project, IDO 8, to the market without partner.
At the moment, Idogen is running two projects in preclinical phase:
IDO 8 is Idogen’s most advanced project, aimed at developing a tolerogenic cell therapy for patients with severe haemophilia A who have developed inhibitory antibodies against their standard treatment. The first clinical trial is planned to commence at the end of 2018.
The same method that is currently under development for the treatment of haemophilia A can also be used for other indications with only minor adjustments of the production process. The company has therefore made a strategic decision to commence parallel development of a product candidate for kidney transplantation, IDO T. The basic principle is to “teach” the patient’s immune system to recognise and accept the transplanted organ rather than attack it. Preclinical development for IDO T is ongoing with the aim of commencing a Phase I/IIa clinical trial in 2019.
The area of use for Idogen´s technology can be further expanded. In autoimmune diseases, the body’s immune system attacks self-antigens, but this may be prevented by reprogramming the immune system with Idogen’s technology.
Idogen will seek cooperation with external partners for most new diseases that may be relevant. If the company’s technology proves to function for IDO 8 and IDO T, the possibility of early collaborative projects in other diseases is considered as realistic and attractive.
For further information or interest regarding collaborations, please contact CEO Lars Hedbys, Lars.Hedbys[at]idogen.com.